| 常用名 | 维汀-利法妥珠单抗 | CAS号 | 1401812-88-1 |
|---|---|---|---|
| 价格 | 纯度 | 90.0% | |
| 备货期 | 10天 | 库存 | 现货 |
| 产品详情(用途,包装等)
用途: Lifastuzumab vedotin (DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research[1]. 物理化学性质: CAS号:1401812-88-1 常用中文名:维汀-利法妥珠单抗 常用英文名:Lifastuzumab Vedotin 分子式: 分子量: 密度:N/A 沸点:N/A 熔点:N/A 闪点:N/A |